secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001171843-24-001515
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024
--------------------------------------------------------------------------------

- Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.
- Cash and marketable securities $152.5M at Dec 31, 2023; runway into mid-2026.
- CTX-009 Phase 2/3 BTC study (COMPANION-002) enrollment ongoing; top-line data expected year-end 2024.
- CTX-009 Phase 2 CRC study (COMPANION-003) Stage 1 enrollment complete; top-line data mid-2024.
- CTX-471 Phase 2 monotherapy planning underway for melanoma with novel biomarker; combination arm with KEYTRUDA enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/0001171843-24-001515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/f8k_032024.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer